Barclays PLC Has $43,000 Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV)

Barclays PLC grew its position in shares of Elevation Oncology, Inc. (NASDAQ:ELEV) by 302.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,077 shares of the company’s stock after acquiring an additional 54,167 shares during the quarter. Barclays PLC owned about 0.12% of Elevation Oncology worth $43,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Rhumbline Advisers bought a new stake in Elevation Oncology during the 2nd quarter valued at $175,000. American Century Companies Inc. increased its position in shares of Elevation Oncology by 55.7% during the second quarter. American Century Companies Inc. now owns 49,222 shares of the company’s stock worth $133,000 after acquiring an additional 17,602 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Elevation Oncology in the 2nd quarter worth about $103,000. Frazier Life Sciences Management L.P. bought a new position in Elevation Oncology in the 2nd quarter valued at about $7,988,000. Finally, SG Americas Securities LLC acquired a new position in Elevation Oncology during the 3rd quarter valued at about $28,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Elevation Oncology Price Performance

Shares of Elevation Oncology stock opened at $0.66 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 17.77 and a current ratio of 17.77. The stock has a market capitalization of $39.13 million, a price-to-earnings ratio of -0.81 and a beta of 1.28. The company has a fifty day moving average of $0.65 and a 200-day moving average of $0.91. Elevation Oncology, Inc. has a 52-week low of $0.50 and a 52-week high of $5.83.

Elevation Oncology (NASDAQ:ELEV) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.02). Equities research analysts expect that Elevation Oncology, Inc. will post -0.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Stephens reissued an “overweight” rating and issued a $5.00 price objective on shares of Elevation Oncology in a research note on Friday, December 6th. JMP Securities restated a “market outperform” rating and set a $7.00 price objective on shares of Elevation Oncology in a research note on Thursday, December 19th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Elevation Oncology in a report on Tuesday, January 14th. Finally, William Blair began coverage on shares of Elevation Oncology in a report on Friday, January 3rd. They issued an “outperform” rating for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $7.20.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.